Clinical trial
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults…
NCT02604433 · Celgene, Industry · Completed
Key facts
| NCT number | NCT02604433 |
|---|---|
| Title | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia |
| Official title | A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia |
| Acronym | BELIEVE |
| Lead sponsor | Celgene, Industry |
| Collaborators | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Erythrocyte Transfusion, Beta-Thalassemia |
| Intervention type | Drug, Other |
| Interventions | Luspatercept, Placebo |
| Enrollment | 336 |
| Start date | May 2, 2016 |
| Primary completion | Jan 5, 2021 |
| Completion | Jan 5, 2021 |
| First posted | Nov 13, 2015 |
| Last update posted | Apr 18, 2023 |
| Countries | Australia, Bulgaria, Canada, France, Greece, Israel, Italy, Lebanon, Malaysia, Taiwan, Thailand, Tunisia and 3 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: